Your journey
1What's a trial
2Find
3Review
4Get in touch
More info
You can access this
clinical trial
if you have
Repeated Implantation Failure
and you are
between 20 and 40
years old
1
This is an early phase trial to determine
the dosage and safety of the new treatment.
Show me locations

The purpose

This study intends to carry out a prospective, randomized, double blind and controlled study to compare the influence of Atosiban and placebo on uterine contraction frequency, endometrial blood flow perfusion, oxytocin and serum concentration of PGF2α, embryo implantation rate and clinical pregnancy rate on the RIF population after fresh embryo transfer, so as to further clarify the curative effect of Atosiban in the treatment of RIF and provide evidence-based basis for Atosiban for application in RIF population.

Provided treatments

  • Drug: atosiban
  • Drug: 0.9% saline
Wondering what is the locations section for?
We will connect you to the doctor responsible for this trial and help you get more information.

Locations near you

Unfortunately, there are no recruiting locations near you. Please check the list with all locations below.
Tris trial is registered with FDA with number: NCT02893722. The sponsor of the trial is Shanghai First Maternity and Infant Hospital and it is looking for 200 volunteers for the current phase.
Official trial title:
A Randomized Double Blind Comparison of Atosiban in Patients With Repeated Implantation Failure Undergoing IVF Treatment